Log In
Print
BCIQ
Print
Print this Print this
 

tildrakizumab (MK-3222) (formerly SCH 900222)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionAnti-IL-23 antibody
Molecular Target Interleukin-23 (IL-23)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationPsoriasis
Indication DetailsTreat moderate to severe chronic plaque psoriasis
Regulatory Designation

Partner

Sun Pharmaceutical Industries Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today